- ICH GCP
- EU: s kliniska prövningsregister
Senaste försöken
EudraCT Number: 2022-002014-16 | Sponsor Protocol Number: VIR-MHB1-V200 | Start Date: 2023-04-12 | |||||||||||
Sponsor Name: Vir Biotechnology, Inc. | |||||||||||||
Full Title: A Platform Study Evaluating the Efficacy and Safety of Investigational Therapies in Participants with Chronic Hepatitis B Infection (PREVAIL) | |||||||||||||
Medical condition: Chronic Hepatitis B Virus (HBV) Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002751-19 | Sponsor Protocol Number: 82160 | Start Date: 2023-04-11 | ||||||
Sponsor Name: Amsterdam UMC | ||||||||
Full Title: FAPi-PET imaging of in vivo fibrosis in inflammatory bowel disease patients | ||||||||
Medical condition: Inflammatory Bowel Diseases | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: NL (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002746-40 | Sponsor Protocol Number: VX22-864-108 | Start Date: 2023-04-11 | |||||||||||
Sponsor Name: Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 2, Open-label Study Evaluating Efficacy and Safety of VX-864 in Subjects With Alpha-1 Antitrypsin Deficiency Who Have the PiZZ Genotype, Over 48 Weeks | |||||||||||||
Medical condition: Alpha 1 antitrypsin deficiency in Subjects With the PiZZ Genotype | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002965-13 | Sponsor Protocol Number: TAK-861-2003 | Start Date: 2023-04-11 | |||||||||||
Sponsor Name: Takeda Development Center Americas, Inc. | |||||||||||||
Full Title: A Long-term Extension Study to Evaluate the Safety and Tolerability of TAK-861 in Participants With Selected Central Hypersomnia Conditions | |||||||||||||
Medical condition: Narcolepsy with Cataplexy (Type 1) and Narcolepsy without Cataplexy (Type 2) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Ongoing) IT (Ongoing) ES (Ongoing) NL (Ongoing) FR (Trial now transitioned) SE (Trial now transitioned) FI (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001189-40 | Sponsor Protocol Number: APD811-303 | Start Date: 2023-04-05 | |||||||||||
Sponsor Name: Arena Pharmaceuticals, Inc. | |||||||||||||
Full Title: A StuDy EVAluatiNg the Long-Term EffiCacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION | |||||||||||||
Medical condition: Pulmonary arterial hypertension (PAH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) SE (Prematurely Ended) GB (GB - no longer in EU/EEA) CZ (Ongoing) BE (Ongoing) DK (Ongoing) NL (Ongoing) HU (Ongoing) BG (Ongoing) GR (Ongoing) PL (Ongoing) PT (Ongoing) HR (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001547-25 | Sponsor Protocol Number: ZILO-301 | Start Date: 2023-04-04 | |||||||||||||||||||||
Sponsor Name: Oncternal Therapeutics, Inc | |||||||||||||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Zilovertamab (an ROR1 Antibody) Plus Ibrutinib Versus Ibrutinib Plus Placebo in Subjects with Relapsed or Refractory Ma... | |||||||||||||||||||||||
Medical condition: Relapsed or Refractory Mantle Cell Lymphoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: HU (Prematurely Ended) ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000838-34 | Sponsor Protocol Number: NOE-TCS-201 | Start Date: 2023-04-04 | |||||||||||
Sponsor Name: Noema Pharma AG | |||||||||||||
Full Title: A Phase 2B, Multicenter, 30-week, Prospective, Cross-over, Doubleblind, Randomized, Placebo-controlled Study Followed by a 52-Week Open-label Extension Study to Evaluate the Efficacy and Safety of ... | |||||||||||||
Medical condition: Tuberous Sclerosis Complex | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) ES (Ongoing) PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001114-19 | Sponsor Protocol Number: IB2022-01 | Start Date: 2023-04-03 | |||||||||||
Sponsor Name: Institut Bergonié | |||||||||||||
Full Title: Lurbinectedin combined with durvalumab (MEDI 4736) in pre-treated patients with extensive stage small-cell lung cancer | |||||||||||||
Medical condition: platinum sensitive extensive stage small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002440-40 | Sponsor Protocol Number: TX200-KT03 | Start Date: 2023-03-31 | |||||||||||
Sponsor Name: Sangamo Therapeutics France SAS | |||||||||||||
Full Title: Long-Term Follow-Up of Patients who have received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (CAR- Treg therapy, TX200-TR101) in a prior clinical study. | |||||||||||||
Medical condition: Prevention of immune mediated allograft rejection in patients with end-stage renal disease (ESRD) who are tissue typed as HLA-A*02 negative and have received a kidney transplant from an HLA-A*02 p... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001786-12 | Sponsor Protocol Number: CDX0159-08 | Start Date: 2023-03-31 | |||||||||||
Sponsor Name: Celldex Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis (The "EvolvE" Study) | |||||||||||||
Medical condition: Eosinophilic esophagitis (EoE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) IT (Ongoing) PL (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |